1 Hasse B, Huttner A, Huttner B, Egger M, Zanetti G, Marschall J, Mühlemann K, Harbarth S. Behandlung von unkomplizierten Harnwegsinfekten, Guidelines des schweizerischen Gesellschaft für Infektiologie. https://ssi.guidelines.ch
2 Leitlinienprogramm DGU: Interdisziplinare S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion 1.1-2, 2017 AWMF Registernummer: 043/044, http://www.awmf.org/uploads/tx_szleitlinien/043-044l_S3_Harnwegsinfektionen
3 Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.
4 Holmberg L, Boman G, Bottiger LE, Eriksson B, Spross R, Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med. 1980;69:733–8.
5 Jick SS, Jick H, Walker AM, Hunter JR. Hospitalizations for pulmonary reactions following nitrofurantoin use. Chest. 1989;96(3):512–5.
6 Chudnofsky CR, Otten EJ. Acute pulmonary toxicity to nitrofurantoin. J Emerg Med. 1989;7(1):15–9.
7 Madani Y, Mann B. Nitrofurantoin induced lung disease and prophylaxis of urinary tract infektions. Prim Care Respir J. 2012;21(3):337–41.
8 Mullerpattan JB, Dagaonkar RS, Shah HD, Udwadia ZF. Fatal nitrofurantoin lung. J Assoc Physicians India. 2013;61(10):758–60.
9 Williams EM, Triller DM. Recurrent acute nitrofurantoin-induced pulmonary toxicity. Pharmacotherapy. 2006;26(5):713.